Runimotamab
Runimotamab (RG-6194) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control[2].
Product Specifications
CAS Number
2361325-98-4
Product Name Alternative
BTRC-4017A; RG-6194
UNSPSC
12352203
Target
CD3; EGFR
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/runimotamab.html
Purity
99.00
Solubility
10 mM in DMSO
Smiles
[Runimotamab]
Molecular Weight
(146.081 kDa)
References & Citations
[1]Shanu Modi, et al., Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC) . Cancer Res 15 April 2025; 85 (8_Supplement_2) |[2]Michal Rudnik, et al., Abstract 2747: Combined investigation of anti-tumor efficacy and liver safety of bispecific T cell engagers in immune-competent high-throughput co-culturing platform. Cancer Res 1 April 2023; 83 (7_Supplement) : 2747.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
